Thursday, September 10, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

Orion Group Financial Statement Release January–December 2025

View original at globenewswire.com
Orion Group Financial Statement Release January–December 2025 ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October–December 2024: 434.4) million Operating…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The outlook for 2026 does not include any material milestone payments

    80% confidence

  • Sales and marketing expenses are expected to increase in 2026

    80% confidence

  • R&D costs in 2026 will increase from 2025

    80% confidence

  • Animal Health business division is anticipated to grow slightly in 2026

    80% confidence

  • Nubeqa has consistently exceeded expectations, and Orion's annual Nubeqa net sales have the potential to exceed EUR 1 billion by the end of the current decade

    80% confidence

  • Total capital expenditure in 2026 is not expected to have significant changes compared to 2025

    80% confidence

  • Nubeqa royalties and product sales booked by Orion will increase clearly in 2026

    80% confidence

  • Expecting another very strong year in 2026 with continued determined work to build well-being and Orion's future

    80% confidence

  • Orion aims to expand the ODM-212 phase 2 program during 2026

    80% confidence

  • ODM-212 has a lot of potential with its mode of action in various indications beyond rare cancers

    80% confidence

  • Orion delivered a very strong performance in 2025 with solid financial results and clear progress in executing strategy

    80% confidence

  • Branded Products business division is estimated to grow in 2026, driven by Respiratory therapy area and Easyhaler portfolio

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts represent the same entity (JPMorgan Chase & Co.), same attribute (EPS), and same observation date (2025-12-31), which aligns with FY 2025 year-end reporting. Fact A explicitly states FY 2025 with EPS of 20.02 USD/share. Fact B has an unspecified fiscal period (N/A) but reports 4.63 USD, a significantly different value (4.3x lower). Given identical observation dates and the same metric, both facts appear intended to represent FY 2025 annual EPS. The conflicting values (20.02 vs 4.63) constitute a direct contradiction. The N/A period in Fact B suggests incomplete or corrupted metadata rather than legitimate time-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com